Blackhawk Plastic Surgery and other aesthetic practices report rising demand for post-weight-loss body contouring procedures, driven by the GLP-1 agonist boom (semaglutide, tirzepatide). Patients achieving significant weight loss via Ozempic, Wegovy, and Mounjaro are seeking surgical and non-surgical skin tightening, liposuction, and RF body-contouring treatments.
Market
GLP-1 Weight Loss Boom Drives Post-Loss Body Contouring Demand at Aesthetic Practices
Ozempic and semaglutide uptake creates new patient flow for surgical and non-surgical body-sculpting procedures.
GLP-1 weight loss creates new body-contouring demand, expanding RF and surgical procedure volume but concentrating it among larger practices.
This represents a structural shift in aesthetic practice mix: GLP-1 responders create a new patient cohort with defined procedural needs (loose skin, localized fat deposits) and often higher lifetime value. For medspas and surgical practices, this opens RF microneedling and monopolar RF body applications (InMode Forma, Cynosure platforms) as high-margin add-ons to surgical referral networks. However, it also concentrates demand among practices with surgical capability or strong dermatology partnerships—standalone medspas without surgical access may see referral leakage to larger centers.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.